Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Stock-Based Comp

Stock-Based Comp at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc. INDV
$9M+50.0%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$6.26M+7.0%
Avanos Medical logo
Avanos MedicalAVNS
$3.7M-2.6%
Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$13.54M-7.0%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$8.48M+5.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$4.5M-7.6%

Segments

By segment

See full
Segment$10.88M-5.6%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.13B+17.9%
Enterprise value$845.67M-0.3%
P/E15.1×-6.8×
P/S1.4×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s stock-based comp?
Collegium Pharmaceutical, Inc. (COLL) reported stock-based comp of $10.88M in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s stock-based comp changed year-over-year?
Collegium Pharmaceutical, Inc.'s stock-based comp decreased by 5.6% year-over-year, from $11.52M to $10.88M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s stock-based comp has grown at a 14.6% compound annual growth rate (CAGR), from $24.26M to $41.91M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.